Dor BioPharma Signs Collaboration Agreement With IDIS
Dor BioPharma has executed a definitive collaborative agreement with IDIS, for the supply and distribution within the EU of the company’s investigational drug orBec for the treatment of gastrointestinal graft-versus-host disease via a named patient program.
Under a named patient program (NPP), investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the European Medicines Evaluation Agency (EMEA) or a national health authority. The NPP will allow Dor to provide a treatment option to patients with gastrointestinal graft-versus-host disease, an unmet medical need.
John Lagus, vice president of business development at IDIS, said: “We are delighted to be working with Dor to provide patients with gastrointestinal graft-versus-host disease access to orBec, so they can benefit from Dor’s innovative therapy.
“IDIS will work in close partnership with Dor to manage named patient program requests in a way that is reliable and responsible while ensuring that all the regulatory obligations are met.”